Key result
An LVEF of 36-45% was associated with a significantly lower risk of all-cause mortality compared to an LVEF of ≤35% (17% vs 37%, HR 0.52).
Population
685 patients with chronic heart failure and reduced ejection fraction in China, consecutively enrolled and…
Design
Cohort
Follow-up
median 31 months (range, 8-61 months)
Authors
Loading...
Supports LVEF stratification for HFrEF prognosis; leaves open whether intensified GDMT improves outcomes in those with LVEF ≤35%.
Cohort (n=685)
No
Hazard Ratio: 0.52 (95% CI 0.38–0.71)
Absolute Event Rate: 17% vs 37%
p-value: p=0.000
Patients with HFrEF in China have a poor prognosis, particularly those with LVEF ≤35%, and low rates of achieving maximum tolerated doses of guideline-directed medical therapies.
Xu et al. (2013) conducted a cohort in Chronic heart failure with reduced ejection fraction (n=685). LVEF 36-45% vs. LVEF ≤35% was evaluated on All-cause mortality (HR 0.52, 95% CI 0.38-0.71, p=0.000). An LVEF of 36-45% was associated with a significantly lower risk of all-cause mortality compared to an LVEF of ≤35% (17% vs 37%, HR 0.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: